Get Up To Date Event Information

Join our priority contact list and receive the latest event news.

Speaking Opportunities

We are now accepting presentation proposals for the 2012 program. If you are interested in speaking, please contact Barry Walsh using the speaker submission form.

Live tweets from Cell Therapy Bioprocessing 2011

Tweet using #CellTherapyBP

celltherapy A rare podium appearance by Stefan Miltenyi of Miltenyi Biotec now. "Current + Future Trends in CT platform technologies"#CellTherapyBP 18 Oct 2011

celltherapy Miltenyi is betting on point-of-care autologous cell therapy processing not centralized manufacturing. #CellTherapyBP 18 Oct 2011

natashadavie @FDACBER Donald Fink: A big issue is the transition from lab to clinical grade treatments- including reagents #CellTherapyBP 17 Oct 2011

natashadavie Had a great conference, looking forward to next year. Don Fink is a regulatory legend #CellTherapyBP to next year. Don Fink is a regulatory legend 19 Oct 2011

celltherapy Some exciting new innovations in cell therapy bioproduction from large players (e.g, Millipore, Lonza, Pall, Praxair, etc)#CellTherapyBP 17 Oct 2011

celltherapy Lonza's J. Rowley now giving keynote. How cell therapy bioproduction will move from 10B to 50B to 100B to 500B cells per lot#CellTherapyBP 18 Oct 2011

celltherapy Genzyme's S. Duguay: Lessons learned re: multinational mfg sites of a cell therapy product: the MACI case study #CellTherapyBP 18 Oct 2011

celltherapy From a regulatory perspective 'manufacturing' starts at raw materials collection so the rx co is responsible for compliance #CellTherapyBP 18 Oct 2011

celltherapy 4 factors dictating comm success: 1) mature product profile 2) staged financial plan 3) prod characterization 4) COGs + reimb#CellTherapyBP 18 Oct 2011

Over 120 attendees joined IBC's Inaugural Cell Therapy Bioprocessing Conference in Reston, VA this past October to learn, interact and exchange ideas with the industry's best scientists, engineers, and executives during the intensive 2 day agenda that extensively covered the full spectrum of unique bioprocessing challenges and opportunities in cell therapy.

The tone for the conference was set early as Dr. Robert Willenbucher and Dr. Kurt Gunter delivered great keynotes that examined the current trends and future directions of the cell therapy market. They were followed by Dr. Donald Fink of the FDA, who delivered a featured presentation on a CMC reviewer's perspective on overcoming the challenge of manufacturing a deliverable cell therapy product and Dr. Paula Salmikangas of the Finnish Medicines Agency to give the European perspective on manufacturing and testing cell-based medicinal products. The focus then shifted to development and product characterization, upstream process development and downstream process development as presenters shared exclusive case studies and unpublished data with attendees. Day one concluded with a festive cocktail reception which was constantly buzzing with activity as our attendees met with product and service providers and discussed the results from their latest research.

Day two was kicked off by keynotes by Dr. Jon Rowley and Dr. Robert Deans, who both did a wonderful job focusing on the commercial parameters for successful cell therapy bioprocessing. Additional highlights of day two included great industry presentations on process development integrity and control, point-of-care processing and production.

Many attendees commented that this was an unparalleled and much-needed conference that exceeded their expectations because of the fantastic networking opportunities and caliber of speakers and program content, summarized by the following testimonials: